$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414067525 Filed on November 13, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.030M	$860.0K	$270.0K
YoY Change	87.27%	218.52%	-38.64%
% of Gross Profit
Research & Development	$1.640M	$1.572M	$804.0K
YoY Change	92.94%	95.52%	9.84%
% of Gross Profit
Depreciation & Amortization	$30.00K	$30.00K	$30.00K
YoY Change	50.0%	0.0%	-25.0%
% of Gross Profit
Operating Expenses	$2.670M	$2.428M	$1.076M
YoY Change	90.71%	125.65%	-8.19%
Operating Profit		-$2.430M	-$1.081M
YoY Change		124.79%	-6.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$60.00K	$10.00K	-$10.00K
YoY Change	-135.29%	-200.0%	-150.0%
Pretax Income	-$2.730M	-$2.420M	-$1.080M
YoY Change	120.16%	124.07%	-6.09%
Income Tax	$0.00	$0.00	$1.000K
% Of Pretax Income
Net Earnings	-$2.730M	-$2.421M	-$1.082M
YoY Change	123.77%	123.75%	-5.91%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$178.7K	-$159.6K	-$98.63K
COMMON SHARES
Basic Shares Outstanding	15.28M shares	227.4M shares	152.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.540M	$10.57M	$5.120M
YoY Change	144.0%	106.45%	7.11%
Cash & Equivalents	$4.251M	$8.969M	$329.0K
Short-Term Investments	$4.290M	$1.600M	$4.790M
Other Short-Term Assets	$30.00K	$90.00K	$60.00K
YoY Change	0.0%	50.0%	20.0%
Inventory
Prepaid Expenses	$52.00K	$88.00K	$55.00K
Receivables	$1.010M	$450.0K	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.598M	$11.11M	$5.672M
YoY Change	115.88%	95.82%	7.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$313.0K	$270.0K	$267.0K
YoY Change	21.32%	1.12%	-1.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$333.0K	$20.00K	$270.0K
YoY Change	1565.0%	-92.59%	80.0%
Total Long-Term Assets	$313.0K	$293.0K	$540.0K
YoY Change	11.79%	-45.74%	25.58%
TOTAL ASSETS
Total Short-Term Assets	$9.598M	$11.11M	$5.672M
Total Long-Term Assets	$313.0K	$293.0K	$540.0K
Total Assets	$9.911M	$11.40M	$6.212M
YoY Change	109.71%	83.52%	8.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.542M	$1.300M	$446.0K
YoY Change	576.32%	191.48%	134.74%
Accrued Expenses	$1.347M	$820.0K	$710.0K
YoY Change	53.59%	15.49%	-14.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.113M	$2.400M	$1.386M
YoY Change	133.71%	73.16%	26.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$120.0K	$100.0K	$290.0K
YoY Change	-81.82%	-65.52%	81.25%
Total Long-Term Liabilities	$123.0K	$104.0K	$290.0K
YoY Change	-81.22%	-64.14%	81.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.113M	$2.400M	$1.386M
Total Long-Term Liabilities	$123.0K	$104.0K	$290.0K
Total Liabilities	$3.236M	$2.499M	$1.677M
YoY Change	62.86%	49.02%	33.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$61.65M	-$58.92M
YoY Change	17.64%
Common Stock	$68.33M	$67.82M	$55.73M
YoY Change	23.9%	21.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.675M	$8.901M	$4.535M
YoY Change
Total Liabilities & Shareholders Equity	$9.911M	$11.40M	$6.212M
YoY Change	109.71%	83.52%	8.6%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$2.730M	-$2.421M	-$1.082M
YoY Change	123.77%	123.75%	-5.91%
Depreciation, Depletion And Amortization	$30.00K	$30.00K	$30.00K
YoY Change	50.0%	0.0%	-25.0%
Cash From Operating Activities	-$2.010M	-$1.119M	-$713.0K
YoY Change	25.63%	56.94%	-33.61%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	$0.00	$31.00K
YoY Change	600.0%	-100.0%	121.43%
Acquisitions
YoY Change
Other Investing Activities	-$2.690M	-$1.610M	-$3.010M
YoY Change	-156.16%	-46.51%
Cash From Investing Activities	-$2.760M	-$1.606M	-$3.039M
YoY Change	-157.62%	-47.15%	21607.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$104.0K	$3.326M
YoY Change		-103.13%	-32.12%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.00K	$366.0K	$3.326M
YoY Change		-89.0%	-33.85%
NET CHANGE
Cash From Operating Activities	-2.010M	-$1.119M	-$713.0K
Cash From Investing Activities	-2.760M	-$1.606M	-$3.039M
Cash From Financing Activities	50.00K	$366.0K	$3.326M
Net Change In Cash	-4.720M	-$2.359M	-$426.0K
YoY Change	-247.96%	453.76%	-110.81%
FREE CASH FLOW
Cash From Operating Activities	-$2.010M	-$1.119M	-$713.0K
Capital Expenditures	-$70.00K	$0.00	$31.00K
Free Cash Flow	-$1.940M	-$1.119M	-$744.0K
YoY Change	22.01%	50.4%	-31.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2014Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10500000	USD
	bcli	Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus	0.05	pure
	bcli	Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus	0.03	pure
	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8969000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3503000	USD
CY2014Q3	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	450000	USD
CY2013Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	910000	USD
CY2014Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	88000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	11107000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	4446000	USD
CY2014Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	21000	USD
CY2013Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	22000	USD
CY2014Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	104000	USD
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	655000	USD
CY2014Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	104000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	655000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	2499000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1987000	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	67814000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55138000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58923000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52407000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	8901000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	2739000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11400000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4726000	USD
	bcli	Warrant Exercisable Term WarrantExercisableTerm	Exercisable through
	us-gaap	Share Based Compensation ShareBasedCompensation	622000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	764000	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	-64000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	355000	USD
	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	2.25
CY2009	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	74667	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	53333	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15228164	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11750881	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15228164	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11750881	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2068000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3129000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	804000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1572000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1574000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1624000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	272000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	856000	USD
	us-gaap	Operating Expenses OperatingExpenses	3642000	USD
	us-gaap	Operating Expenses OperatingExpenses	4753000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1076000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	2428000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	21000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	1761000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1081000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2419000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1082000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-2421000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.36
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.50
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.10
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.16
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10139618	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13122133	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10948208	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15158411	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3982000	USD
CY2013	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	197000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	186000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2497000	USD
CY2013	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	250000	USD
	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	9554000	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	USD
	bcli	Stock Issued During Period Value Issued For Warrants Exchange StockIssuedDuringPeriodValueIssuedForWarrantsExchange	1633000	USD
	bcli	Adjustments To Additional Paid In Capital Warrant Redemption In Cash AdjustmentsToAdditionalPaidInCapitalWarrantRedemptionInCash	42000	USD
	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	685000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4899000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	77000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	80000	USD
CY2013Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	27000	USD
CY2014Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	30000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	213000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	186000	USD
CY2013Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	11000	USD
CY2014Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	76000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	439000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	578000	USD
CY2013Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	-75000	USD
CY2014Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	280000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-231000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-405000	USD
CY2013Q3	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-198000	USD
CY2014Q3	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-341000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	88000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1076000	USD
CY2013Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	73000	USD
CY2014Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	547000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	188000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-13000	USD
CY2013Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-38000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2446000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2480000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-713000	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1119000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	97000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	USD
CY2013Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	USD
CY2014Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	2017000	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	1600000	USD
CY2013Q3	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	3006000	USD
CY2014Q3	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	1600000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	11000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-1000	USD
CY2013Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	2000	USD
CY2014Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	6000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2125000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1693000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3039000	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1606000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3576000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9554000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3326000	USD
CY2014Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-104000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	685000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2014Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	470000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	600000	USD
CY2013Q3	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014Q3	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3583000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9639000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3326000	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	366000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-988000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5466000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-426000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2359000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1317000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	755000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11328000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	329000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	1633000	USD
CY2013Q3	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	-42000	USD
CY2013Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	0	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	1675000	USD
CY2013Q3	bcli	Noncash Financing Activities NoncashFinancingActivities	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	BRAINSTORM CELL THERAPEUTICS INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001137883
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	BCLI
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15281497	shares
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	1600000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD

Files In Submission

Name	View Source	Status
0001144204-14-067525-index-headers.html	Edgar Link	pending
0001144204-14-067525-index.html	Edgar Link	pending
0001144204-14-067525.txt	Edgar Link	pending
0001144204-14-067525-xbrl.zip	Edgar Link	pending
bcli-20140930.xml	Edgar Link	completed
bcli-20140930.xsd	Edgar Link	pending
bcli-20140930_cal.xml	Edgar Link	unprocessable
bcli-20140930_def.xml	Edgar Link	unprocessable
bcli-20140930_lab.xml	Edgar Link	unprocessable
bcli-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v392478_10q.htm	Edgar Link	pending
v392478_ex31-1.htm	Edgar Link	pending
v392478_ex31-2.htm	Edgar Link	pending
v392478_ex32-1.htm	Edgar Link	pending
v392478_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2014 Q4 Form 10-Q Financial Statement

#000114420414067525 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2014 Q4 Form 10-Q Financial Statement

#000114420414067525 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli